ClinicalTrials.gg

Program

SLX-2101

A development code. Also written as “SLx-2101” and “RTN-001”.

Its studies are mostly in Hypertension · Raynaud Disease, led by 2 companies.

Furthest: phase 2, since Nov 20, 20074 company-led studies, 1 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Retension Pharmaceuticals.31 open or runningphase 2since Nov 20, 2007Nov 20, 2007Mar 2027phase 2 · NCT07142356
Response Pharmaceuticals10 open or runningphase 2since Sep 11, 2007Sep 11, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2007First study: phase 2 study in Raynaud DiseaseNew to Response PharmaceuticalsResponse Pharmaceuticals · NCT00528242 · 17 enrolled · Germany
  2. Nov 20, 2007Retension Pharmaceuticals.'s first studies: 2 phase 2 studies in HypertensionNew to Retension Pharmaceuticals.Retension Pharmaceuticals. · NCT00562614, NCT00562549
  3. Aug 19, 2025Phase 2 study in HypertensionRetension Pharmaceuticals. · NCT07142356 · 280 planned · United States

Ahead

  1. Mar 2027Primary completion: phase 2 study in HypertensionRetension Pharmaceuticals. · NCT07142356

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07142356Hypertension · United States2RecruitingRetension Pharmaceuticals.Mar 2027280
NCT00562614Hypertension · Germany2CompletedRetension Pharmaceuticals.Dec 200738
NCT00562549Hypertension · United Kingdom2CompletedRetension Pharmaceuticals.Dec 200726
NCT00528242Raynaud Disease · Germany2CompletedResponse PharmaceuticalsMar 200817

How it is read

Names in the registry

  • “SLx-2101”, 3 entries
  • “RTN-001”, 1 entry

Codes read as this program: RTN001, SLX2101.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
SLX-2101 (Retension Pharmaceuticals.): development program | ClinicalTrials.gg